Polymorphism in intron 2 of the interleukin-1 receptor antagonist gene, local midtrimester cytokine response to vaginal flora, and subsequent preterm birth - 25/08/11
Abstract |
Objective |
This study investigated the association between polymorphism in intron 2 of the interleukin-1 receptor antagonist gene, midtrimester vaginal microflora, vaginal interleukin receptor antagonist and interleukin-1β levels and subsequent spontaneous preterm birth.
Study design |
Vaginal samples from 212 women, collected at 18-22 weeks' gestation, were analyzed for the polymorphism in intron 2 of the interleukin-1 receptor antagonist gene by polymerase chain reaction, qualitative and quantitative vaginal microflora, and interleukin-1β and interleukin-1ra concentrations by enzyme-linked immunosorbent assay. Pregnancy outcome data were subsequently obtained.
Results |
Carriage of intron 2 of the interleukin-1 receptor antagonist allele 2 (IL1RN2) was associated with an elevated vaginal pH in black (P < .001) and white (P=.005) women, a reduced interleukin-1β response to anaerobic Gram-negative rods and/or Gardnerella vaginalis (P < .01), and a decreased rate of spontaneous preterm deliveries (6% versus 18%, P=.02). In black women, IL1RN2 carriage was associated with increased anaerobic Gram-negative rods, Mycoplasma, and Peptostreptococci and decreased Lactobacilli colonization.
Conclusion |
IL1RN2 carriage was associated with a blunted proinflammatory interleukin-1β response to abnormal vaginal flora. This property may decrease susceptibility to infection-related preterm birth.
Le texte complet de cet article est disponible en PDF.Key words : Genetic polymorphism, Interleukin-1β, Interleukin-1 receptor antagonist, Vaginal microflora, Preterm birth
Plan
Supported by grants RO1-HD-35667 and RO1 HD-41676 from the National Institute of Child Health and Human Development. Presented at the Twenty-Fourth Annual Meeting of the Society for Maternal-Fetal Medicine, February 2-7, 2004, New Orleans, La. |
Vol 191 - N° 4
P. 1324-1330 - octobre 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?